rp-l301
Gene therapyexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2019 (NCT04105166)
Timeline
Indications
Studied for
Mechanism of action
- Pyruvate kinase isozymes R/LSupplementation
PKLR supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06422351 | Phase 2 | Aug 31, 2024 | Hospital Infantil Universitario Niño Jesús, Rocket Pharma Limited, Stanford University, Universidad Autonoma de Madrid |
| NCT04105166 | Phase 1 | Sep 30, 2019 | Rocket Pharma Limited, Universidad Autonoma de Madrid |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Rocket Pharma Limited | For profit | 2 | 2 | 2 | 2019 |
| Universidad Autonoma de Madrid | Academic/Hospital | 2 | 0 | 2 | 2019 |
| Hospital Infantil Universitario Niño Jesús | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Stanford University | Academic/Hospital | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1